Alopecia and Semaglutide: Connecting the Dots for Patient Safety

Recent evidence suggests a potential link between semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight loss, and alopecia. Studies, including a retrospective cohort study by Burke et al. and a scoping review by Tran et al., indicate an increased incidence of hair loss associated with semaglutide. A disproportionality analysis by Godfrey et al. supports these findings, though causality is not confirmed. The rapid weight loss from semaglutide may lead to nutritional deficiencies and endocrine disruptions, contributing to hair loss. The psychosocial impact of alopecia is significant, affecting patient well-being and treatment adherence. There is a critical need for comprehensive clinical trials to confirm these associations and guide safer clinical practices.